ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Respiratory Pharmacology
Clinical Application of Combined Anticoagulation Therapy in Anti-MDA5 Antibody-Positive Associated Interstitial Lung Disease-A Retrospective Study
Provisionally accepted
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To explore the clinical efficacy of combined anticoagulation therapy in patients with anti-Melanoma Differentiation-Associated protein 5 (MDA5) antibody-positive associated interstitial lung disease. Methods: A retrospective cohort study was conducted, which included 100 patients diagnosed with anti-MDA5 antibody-positive interstitial lung disease at our hospital between January 2022 and December 2024. Based on the treatment approach, the patients were divided into two groups: the combined anticoagulation group (receiving conventional therapy plus sequential low-molecular-weight heparin followed by rivaroxaban) and the control group (receiving conventional therapy only). Comparisons were made between the two groups regarding pulmonary function parameters (FVC%, DLCO%, PaO₂), inflammatory markers (CRP, ESR, LDH, CK), as well as the incidence of complications and acute exacerbations. Furthermore, logistic regression analysis was employed to identify independent risk factors for acute exacerbations. Results: At 4-week treatment and 3-month follow-up, the combined anticoagulation group had superior Forced Vital Capacity (FVC)%, Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)%, and Arterial Partial Pressure of Oxygen (PaO₂) levels compared to the control group (P < 0.05). Meanwhile, C-Reactive Protein (CRP), Lactate Dehydrogenase (LDH), and Creatine Kinase (CK) levels decreased significantly. Also, the incidence of complications and acute exacerbation was lower in the combined group (P < 0.05). Logistic regression showed decreased PaO₂, elevated CRP, LDH, and CK, fungal infection, abnormal liver/kidney function, and non-combined anticoagulation as independent acute-exacerbation risk factors. Conclusion: Combined anticoagulation therapy improves pulmonary function, reduces inflammation, and lowers complication and exacerbation risks in anti-MDA5 antibody-positive interstitial lung disease patients. With notable clinical value, it offers a new treatment strategy for this refractory disease.
Keywords: anti-MDA5 antibody, Interstitial Lung Disease, Combined anticoagulation, MAD5, Pulmonary Function
Received: 09 Jul 2025; Accepted: 21 Nov 2025.
Copyright: © 2025 Zhang, Song, Ma, Cao, Lu, Tang and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dongmei Zhou, zdm@xzhmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.